CAMK2G and embryonal carcinoma: In this context, it has been shown that introducing the arrhythmogenic CaM mutation D130G in the CALM2 gene of mouse embryonic carcinoma P19CL6 cells and allowing these cells to differentiate into cardiomyocytes, this procedure decreased their spontaneous beat frequency because of the loss of CaMK-II function [112].